Sooner Clinical Research
Sooner Clinical Research
Oklahoma City, Oklahoma, United States7 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-10-01 | NCT07573176 | |
| Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients | Irritability Associated With Autism Spectrum Disorder | Recruiting | Phase 3 | 2026-09-25 | NCT06706674 | |
| Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder | anxiety disorder, generalized anxiety disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-09-25 | NCT06701903 | |
| Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients | Bipolar and Related Disorders, bipolar disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-09-25 | NCT06372964 | |
| Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder | Bipolar and Related Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, autism spectrum disorder, bipolar disorder, mood disorder, neurodevelopmental disorder, pervasive developmental disorder, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-09-25 | NCT06229210 | |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-09-08 | NCT07076407 | |
| An Open-Label Study of Azetukalner in Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Enrolling by invitation | Phase 3 | 2026-09-03 | NCT06922110 |